芦可替尼联合标准化疗药物在CRLF2重排Ph样急性淋巴细胞白血病中的组合疗效
本研究针对高危、易复发的CRLF2重排Ph样急性淋巴细胞白血病(Ph-like ALL),通过高通量组合药物筛选发现芦可替尼与ALL标准化疗药物具有协同作用,并在2/3的CRLF2重排Ph样ALL异种移植模型中证实芦可替尼可增强长春新碱、地塞米松和左旋天冬酰胺酶诱导方案的体内疗效。
要点
- 芦可替尼与ALL标准化疗药物在CRLF2重排Ph样ALL中显示协同作用
- 芦可替尼增强长春新碱+地塞米松+左旋天冬酰胺酶方案的体内疗效(2/3异种移植模型)
- 结果支持在CRLF2重排Ph样ALL常规诱导方案中加入芦可替尼进行临床评估
核心结论
- 芦可替尼与标准化疗药物联用在CRLF2重排Ph样ALL中具有协同作用,并支持进一步评估其加入常规诱导方案的临床价值。
研究设计与样本
- 临床前研究:采用高通量组合药物筛选、质谱磷酸化蛋白质组学联合基因表达分析及体内异种移植模型药物测试。
主要发现
- 芦可替尼与ALL标准化疗药物在组合筛选中表现出协同作用。
- 芦可替尼增强了长春新碱、地塞米松和左旋天冬酰胺酶诱导方案在2/3的CRLF2重排Ph样ALL异种移植模型中的体内疗效。
临床怎么用
- 对于CRLF2重排Ph样ALL,可考虑在常规诱导方案基础上联合芦可替尼,但需进一步临床验证。
局限性
- 研究为临床前阶段,样本量有限(2/3异种移植模型有效),尚未在患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk ALL subtype with high rates of relapse and poor patient outcome. Activating mutations affecting components of the JAK-STAT signaling pathway occur in the majority of Ph-like ALL cases. The use of JAK inhibitors represents a potential treatment option for Ph-like ALL, although we and others have shown that CRLF2-rearranged Ph-like ALL responds poorly to single-agent JAK inhibitors in the preclinical setting. Therefore, the aim of this study was to identify effective combination treatments against CRLF2-rearranged Ph-like ALL, and to elucidate the underlying mechanisms of synergy. We carried out a series of high-throughput combination drug screenings and found that ruxolitinib exerted synergy with standard-of-care drugs used in the treatment of ALL. In addition, we investigated the molecular effects of ruxolitinib on Ph-like ALL by combining mass spectrometry phosphoproteomics with gene expression analysis. Based on these findings, we conducted preclinical in vivo drug testing and demonstrated that ruxolitinib enhanced the in vivo efficacy of an induction-type regimen consisting of vincristine, dexamethasone, and L-asparaginase in 2/3 CRLF2-rearranged Ph-like ALL xenografts. Overall, our findings support evaluating the addition of ruxolitinib to conventional induction regimens for the treatment of CRLF2-rearranged Ph-like ALL.
引用
- Bӧhm JW, Sia KCS, Jones C, et al. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia. Leukemia. 2021. PMID: 33895784. doi:10.1038/s41375-021-01248-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。